• Home
• People
  • Management
  • Scientific Advisors
  • Clinical Advisors
• Technology
• Product Pipeline
  • Vaccines
  • Tumor Immunotherapy
  • CD40-B Cell Immunotherapy
  • Precision Immunization™
• Presentations
• Publications
• News
• Intellectual Property
• About MultimericBio
  • Company
  • Investors
• Contact

Recent Presentations

Vaccine adjuvant and anti-tumor effects of a multimeric form of  GITR Ligand (GITRL) that abrogates Treg-mediated suppression

Cancer Research Institute Symposium 2010, Multiple Functions of CD4 T Cells in Autoimmunity, Infectious Disease, and Cancer

October 6, 2010, New York, NY, PDF of poster (2 MB)

CD40L and other TNF SuperFamily ligands as vaccine adjuvants

BIO 2010, Session 4834, Innovations in Vaccines

May 3, 2010, Chicago, Illinois, PDF of podium presentation

Enhanced vaccine and anti-tumor immunity using GITR ligand (GITRL) or extracellular ATP (ATPe)

T Cell Regulation and Autoimmunity, 12th International Conference on Lymphocyte Activation and Immune Regulation

February 9, 2008, Newport Beach, California, PDF of poster presentation

Markedly improved antibody responses to DNA vaccination for HIV envelope using CD8+ T cells and BAFF

AIDS Vaccine 2007 Conference

August 14, 2007, Seattle, Washington, PDF of poster presentation

Applications of multimeric, soluble TNFSFs to vaccination and tumor immunotherapy

International TNF Conference 2007

May 14, 2007, Asilomar, California, PDF of poster presentation

Treatment of established tumors with peritumoral injections of CD40 ligand (CD40L), CpG, poly(I:C), and extracellular ATP in murine models

International Society for Biological Therapy of Cancer (iSBTc)

November 1, 2007, Boston, Massachusetts, PDF of podium presentation